UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2307-2313

2012

Volltextzugriff (PDF)

Phase 2 to Phase 3 Clinical Trial Transitions: Reasons for Success and Failure in Immunologic Diseases

Journal of allergy and clinical immunology, 2017-09, Vol.140 (3), p.685-687

2017

Volltextzugriff (PDF)

Structural Basis for Recruitment of CBP/p300 by Hypoxia-Inducible Factor-1α

Proceedings of the National Academy of Sciences - PNAS, 2002-04, Vol.99 (8), p.5367-5372

2002

Volltextzugriff (PDF)

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Blood, 2007-01, Vol.109 (2), p.500-502

2007

Volltextzugriff (PDF)

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

Cancer cell, 2004-07, Vol.6 (1), p.33-43

2004

Volltextzugriff (PDF)

Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2

Nature structural & molecular biology, 2003-07, Vol.10 (7), p.504-512

2003

Volltextzugriff (PDF)

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2011-02, Vol.67 (2), p.305-314

2011

Volltextzugriff (PDF)

Structure of the Calcium Ion-Bound .gamma.-Carboxyglutamic Acid-Rich Domain of Factor IX

Biochemistry (Easton), 1995-09, Vol.34 (38), p.12126-12137

1995

Volltextzugriff (PDF)

Homotetrameric Structure of the SNAP-23 N-terminal Coiled-coil Domain

Proceedings of the National Academy of Sciences - PNAS, 2003-04, Vol.278 (15), p.13462-13467

2003

Volltextzugriff (PDF)

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

Cancer chemotherapy and pharmacology, 2007-03, Vol.59 (3), p.407-412

2007

Volltextzugriff (PDF)

Three Conformational States of the p300 CH1 Domain Define Its Functional Properties

Biochemistry (Easton), 2003-08, Vol.42 (33), p.9937-9945

2003

Volltextzugriff (PDF)

Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX

The Journal of biological chemistry, 1996-07, Vol.271 (27), p.16227-16236

1996

Volltextzugriff (PDF)

November 2002: a 72-year-old woman with a pineal gland mass

Brain pathology (Zurich, Switzerland), 2003-04, Vol.13 (2), p.235-239

2003

Volltextzugriff (PDF)

Interaction between Soluble P-Selectin and Soluble P-Selectin Glycoprotein Ligand 1: Equilibrium Binding Analysis

Biochemistry (Easton), 1998-11, Vol.37 (47), p.16472-16480

1998

Volltextzugriff (PDF)

Refinement of the NMR Solution Structure of the γ-Carboxyglutamic Acid Domain of Coagulation Factor IX Using Molecular Dynamics Simulation with Initial Ca2+ Positions Determined by a Genetic Algorithm

Biochemistry (Easton), 1997-02, Vol.36 (8), p.2132-2138

1997

Volltextzugriff (PDF)

Profactor IX: The propeptide inhibits binding to membrane surfaces and activation by factor XIA

Biochemistry (Easton), 1994-11, Vol.33 (47), p.14136-14143

1994

Volltextzugriff (PDF)

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Blood, 2011-11, Vol.118 (21), p.1856-1856

2011

Volltextzugriff (PDF)

Structure and Function of the Epidermal Growth Factor Domain of P-Selectin

Biochemistry (Easton), 1996-10, Vol.35 (43), p.13733-13744

1996

Volltextzugriff (PDF)

Translational In Vivo and In Vitro Studies in Patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor

Blood, 2006-11, Vol.108 (11), p.1362-1362

2006

Volltextzugriff (PDF)

Developing technologies in biodefense research: computational drug design

Drug development research, 2009-06, Vol.70 (4), p.279-287

2009

Volltextzugriff (PDF)

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation

Blood, 2006-11, Vol.108 (11), p.637-637

2006

Volltextzugriff (PDF)

MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL

Blood, 2006-11, Vol.108 (11), p.1967-1967

2006

Volltextzugriff (PDF)

MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD)

Blood, 2006-11, Vol.108 (11), p.4893-4893

2006

Volltextzugriff (PDF)

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Commentary

Blood, 2007, Vol.109 (2)

2007

Volltextzugriff (PDF)

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML)

Blood, 2006-11, Vol.108 (11), p.163-163

2006

Volltextzugriff (PDF)

1 – 25 von 499

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(476)
Mit Volltextzugriff
(406)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(498)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Phase 2 to Phase 3 Clinical Trial Transitions: Reasons for Success and Failure in Immunologic Diseases

Structural Basis for Recruitment of CBP/p300 by Hypoxia-Inducible Factor-1α

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Structure of the Calcium Ion-Bound .gamma.-Carboxyglutamic Acid-Rich Domain of Factor IX

Homotetrameric Structure of the SNAP-23 N-terminal Coiled-coil Domain

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

Three Conformational States of the p300 CH1 Domain Define Its Functional Properties

Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX

November 2002: a 72-year-old woman with a pineal gland mass

Interaction between Soluble P-Selectin and Soluble P-Selectin Glycoprotein Ligand 1: Equilibrium Binding Analysis

Refinement of the NMR Solution Structure of the γ-Carboxyglutamic Acid Domain of Coagulation Factor IX Using Molecular Dynamics Simulation with Initial Ca2+ Positions Determined by a Genetic Algorithm

Profactor IX: The propeptide inhibits binding to membrane surfaces and activation by factor XIA

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Structure and Function of the Epidermal Growth Factor Domain of P-Selectin

Translational In Vivo and In Vitro Studies in Patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor

Developing technologies in biodefense research: computational drug design

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation

MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL

MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD)

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Commentary

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML)

Suchergebnisse filtern